Chemistry:Henagliflozin
From HandWiki
Henagliflozin is a pharmaceutical drug for the treatment of type 2 diabetes.[1] In China, it is approved for adult patients with type 2 diabetes to improve the glycemic control.[2][3]
Henagliflozin, like other drugs of the gliflozin class, inhibits the transporter protein sodium/glucose cotransporter 2 (SGLT2) which leads to a reduction in blood glucose levels.[4]
In a 26-week placebo-controlled trial of type 2 diabetics, telomere length significantly lengthened, the IGF-1 pathway was inhibited, and immune system function was improved in the henagliflozin group compared to the placebo group.[5]
References
- ↑ "Henagliflozin as add-on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double-blind, placebo-controlled, phase 3 trial". Diabetes, Obesity & Metabolism 23 (8): 1754–1764. August 2021. doi:10.1111/dom.14389. PMID 33769656.
- ↑ "Monthly Report: New Drug Approvals in China, January 2022". BaiPharm. 17 February 2022. https://baipharm.chemlinked.com/news/monthly-report-new-drug-approvals-in-china-january-2022. "Henagliflozin Proline Tablets"
- ↑ "Henagliflozin - Jiangsu HengRui Medicine". AdisInsight. Springer Nature Switzerland AG. https://adisinsight.springer.com/drugs/800041987.
- ↑ "Pharmacokinetic and Pharmacodynamic Interactions Between Henagliflozin, a Novel Selective SGLT-2 Inhibitor, and Warfarin in Healthy Chinese Subjects". Clinical Therapeutics 45 (7): 655–661. July 2023. doi:10.1016/j.clinthera.2023.06.002. PMID 37451912.
- ↑ "Effect of henagliflozin on aging biomarkers in patients with type 2 diabetes: A multicenter, randomized, double-blind, placebo-controlled study". Cell Reports 6 (9). 2025. doi:10.1016/j.xcrm.2025.102331. PMID 40912255.
 |  |
